To include your compound in the COVID-19 Resource Center, submit it here.

EC145: Additional Phase II data

Additional data from the open-label, international Phase II PRECEDENT trial in 149 patients with platinum-resistant ovarian cancer showed that thrice-weekly 2.5 mg IV EC145 every 2 weeks plus 50 mg/m 2 IV Doxil

Read the full 334 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers